Clinical trial · Observational
AI Multitask Model for HCC Treatment
AI-Driven Multitask Model for Guiding Treatment Decision-Making in Hepatocellular Carcinoma
NCT07157085CI-TRIAL-00094626completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma. The resulting tool will be prospectively deployed to guide personalized surgical, TACE, and systemic therapy decisions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Comprehensive treatment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 60 months
- description
- from diagnosis of HCC to death or last follow-up
Secondary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 60 months
- description
- from diagnosis of HCC to disease progression or last follow-up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. age 18-75 years; 2. HCC diagnosed according to the European Association for the Study of the Liver/American Association for the Study of Liver Diseases criteria) 3. Eastern Cooperative Oncology Group performance status \< 2; 4. Child-Pugh class A or B liver function; Exclusion Criteria: 1. HCC combined with other malignancies; 2. missing image data during perioperative period; 3. lost to follow-up \> 12 months.
References
Publications (0)
Data not yet available
No reference posted for this study.